1. Home
  2. UCL vs JSPR Comparison

UCL vs JSPR Comparison

Compare UCL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$0.38

Market Cap

27.8M

ML Signal

HOLD

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.70

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
JSPR
Founded
2014
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8M
26.3M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
UCL
JSPR
Price
$0.38
$0.70
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
1.3M
720.1K
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.60
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.32
52 Week High
$3.58
$2.87

Technical Indicators

Market Signals
Indicator
UCL
JSPR
Relative Strength Index (RSI) 25.48 48.24
Support Level N/A $0.61
Resistance Level $0.99 $1.01
Average True Range (ATR) 0.07 0.10
MACD -0.02 -0.01
Stochastic Oscillator 4.59 12.84

Price Performance

Historical Comparison
UCL
JSPR

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: